Ameritas Investment Partners’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $336K | Buy |
10,685
+1,013
| +10% | +$29.9K | 0.01% | 1076 |
|
|
2026
Q1 | $239K | Hold |
9,672
| – | – | 0.01% | 1160 |
|
|
2025
Q4 | $226K | Hold |
9,672
| – | – | 0.01% | 1186 |
|
|
2025
Q3 | $191K | Sell |
9,672
-2,024
| -17% | -$41.6K | 0.01% | 1268 |
|
|
2025
Q2 | $254K | Hold |
11,696
| – | – | 0.01% | 1159 |
|
|
2025
Q1 | $284K | Hold |
11,696
| – | – | 0.01% | 1075 |
|
|
2024
Q4 | $244K | Buy |
11,696
+580
| +5% | +$12.5K | 0.01% | 1207 |
|
|
2024
Q3 | $221K | Hold |
11,116
| – | – | 0.01% | 1251 |
|
|
2024
Q2 | $172K | Hold |
11,116
| – | – | 0.01% | 1374 |
|
|
2024
Q1 | $177K | Buy |
11,116
+720
| +7% | +$10.8K | 0.01% | 1369 |
|
|
2023
Q4 | $175K | Buy |
10,396
+816
| +9% | +$11.2K | 0.01% | 1356 |
|
|
2023
Q3 | $112K | Buy |
9,580
+1,977
| +26% | +$26.4K | ﹤0.01% | 1575 |
|
|
2023
Q2 | $102K | Hold |
7,603
| – | – | ﹤0.01% | 1593 |
|
|
2023
Q1 | $126K | Hold |
7,603
| – | – | 0.01% | 1381 |
|
|
2022
Q4 | $112K | Hold |
7,603
| – | – | ﹤0.01% | 1514 |
|
|
2022
Q3 | $97K | Hold |
7,603
| – | – | ﹤0.01% | 1509 |
|
|
2022
Q2 | $53K | Hold |
7,603
| – | – | ﹤0.01% | 1948 |
|
|
2022
Q1 | $63K | Hold |
7,603
| – | – | ﹤0.01% | 1925 |
|
|
2021
Q4 | $51K | Sell |
7,603
-1,460
| -16% | -$9.6K | ﹤0.01% | 2112 |
|
|
2021
Q3 | $48K | Hold |
9,063
| – | – | ﹤0.01% | 2180 |
|
|
2021
Q2 | $52K | Hold |
9,063
| – | – | ﹤0.01% | 2144 |
|
|
2021
Q1 | $42K | Hold |
9,063
| – | – | ﹤0.01% | 2183 |
|
|
2020
Q4 | $30K | Hold |
9,063
| – | – | ﹤0.01% | 2274 |
|
|
2020
Q3 | $27K | Hold |
9,063
| – | – | ﹤0.01% | 2210 |
|
|
2020
Q2 | $42K | Hold |
9,063
| – | – | ﹤0.01% | 1934 |
|
|
2020
Q1 | $35K | Hold |
9,063
| – | – | ﹤0.01% | 1857 |
|
|
2019
Q4 | $34K | Hold |
9,063
| – | – | ﹤0.01% | 2125 |
|
|
2019
Q3 | $48K | Hold |
9,063
| – | – | ﹤0.01% | 1895 |
|
|
2019
Q2 | $35K | Hold |
9,063
| – | – | ﹤0.01% | 2115 |
|
|
2019
Q1 | $46K | Hold |
9,063
| – | – | ﹤0.01% | 1924 |
|
|
2018
Q4 | $17K | Hold |
9,063
| – | – | ﹤0.01% | 2429 |
|
|
2018
Q3 | $34K | Hold |
9,063
| – | – | ﹤0.01% | 2200 |
|
|
2018
Q2 | $28K | Buy |
9,063
+2,783
| +44% | +$8.44K | ﹤0.01% | 2309 |
|
|
2018
Q1 | $15K | Hold |
6,280
| – | – | ﹤0.01% | 2552 |
|
|
2017
Q4 | $25K | Hold |
6,280
| – | – | ﹤0.01% | 2322 |
|
|
2017
Q3 | $17K | Hold |
6,280
| – | – | ﹤0.01% | 2509 |
|
|
2017
Q2 | $17K | Buy |
+6,280
| New | +$13.1K | ﹤0.01% | 2551 |
|
Other funds holding CPRX
GCL
HI
Ameritas Investment Partners's CPRX Position: Q2 2026 in Review
Ameritas Investment Partners increased its Catalyst Pharmaceutical (CPRX) stake by 10% in Q2 2026, buying an estimated $29.9K and bringing the position to 10,685 shares worth $336K. The position accounts for 0.01% of the portfolio, ranked #1076.
Ameritas Investment Partners first reported a position in CPRX in Q2 2017 and has held it in 37 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.
- Ameritas Investment Partners held 10,685 shares of Catalyst Pharmaceutical worth $336K as of Q2 2026.
- Ameritas Investment Partners bought 1,013 Catalyst Pharmaceutical shares in Q2 2026, an estimated $29.9K.
- Catalyst Pharmaceutical made up 0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #1076 holding.
- Ameritas Investment Partners first reported a position in Catalyst Pharmaceutical in Q2 2017 and has held it in 37 quarters since.
- 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.
Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.